Cinpanemab

Cinpanemab ( , ; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Cinpanemab ( , ; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease. It showed no significant influence on disease progression in a 52-week phase 2 clinical trial. The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness. It was under development by Biogen.

See also

List of investigational Parkinson's disease drugs Prasinezumab

Cinpanemab - AlzForum

Text derived from https://en.wikipedia.org/w/index.php?oldid=1335373292 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.